Goldman Sachs’s Oncolytics Biotech ONCY Stock Holding History
Bought
Maintained
Sold
Other funds holding ONCY
IAIM
Goldman Sachs's ONCY Position: Q3 2026 in Review
Goldman Sachs increased its Oncolytics Biotech (ONCY) stake by 9.9% in Q3 2026, buying an estimated $13.6K and bringing the position to 186,639 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #6309.
Goldman Sachs first reported a position in ONCY in Q1 2021 and has held it in 11 quarters since. The position peaked at $292K in Q3 2025. 77 funds tracked by Wall St. Rank hold ONCY as of Q3 2026.
- Goldman Sachs held 186,639 shares of Oncolytics Biotech worth $125K as of Q3 2026.
- Goldman Sachs bought 16,741 Oncolytics Biotech shares in Q3 2026, an estimated $13.6K.
- Oncolytics Biotech made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #6309 holding.
- Goldman Sachs first reported a position in Oncolytics Biotech in Q1 2021 and has held it in 11 quarters since.
- Goldman Sachs's Oncolytics Biotech position peaked at $292K in Q3 2025.
- 77 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2026.
Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.